Firm at a glance
Afinum is a platform private equity firm founded in 2000 and headquartered in Munich, Germany, per its own website [S1].
What they buy
Afinum operates across German-speaking Europe with offices in Munich, Frankfurt, and Zurich [S1]. The firm has accumulated approximately €1.8 billion in total capital commitments across six fund generations as of April 2026 [S1]. Recent transaction activity indicates focus areas spanning technology services, engineering, pharmaceuticals, and industrial technology, based on publicly disclosed acquisitions between 2024 and 2026 [S2][S3].
Portfolio
No current portfolio companies were surfaced in the public materials reviewed as of April 2026. Recent acquisitions and exits are detailed in the activity section below.
Recent activity (last 24 months)
* **April 2026**: Acquired sequrio GmbH [S2]
* **February 2026**: Acquired p36 GmbH [S2]
* **January 2026**: Acquired Ergon Informatik AG [S2]
* **January 2026**: Exited Kappa optronics GmbH [S2]
* **January 2026**: Exited Threema Holding AG [S2]
* **December 2025**: Acquired DPS Engineering GmbH [S2]
* **September 2024**: Acquired ProJect Pharmaceutics, a formulation development specialist [S3]
How this firm fits a seller
Afinum demonstrates consistent acquisition activity through early 2026, completing five platform acquisitions in the trailing 18 months alongside two exits [S2][S3]. The firm’s multi-office presence across German-speaking markets positions it for businesses operating in Germany, Austria, and Switzerland [S1]. The recent exit activity suggests the firm actively manages portfolio lifecycle, which may appeal to sellers seeking a buyer with demonstrated realization experience. Businesses in technology services, specialized engineering, or pharmaceutical development may find sector alignment based on observed transaction patterns [S2][S3].
Sources
[S1] https://afinum.de (as of 2026-04-27)
[S2] https://afinum.de/news/ (as of 2026-04-27)
[S3] https://www.orrick.com/en/news/2025/09/afinum-invests-in-formulation-development-specialist-project-pharmaceutics (as of 2024-09-23)
Frequently asked questions
Does Afinum buy technology businesses?
Recent acquisitions include sequrio GmbH, p36 GmbH, and Ergon Informatik AG, all completed in the first quarter of 2026, suggesting active interest in technology-related platforms [S2]. The firm also exited Threema Holding AG in January 2026, indicating prior investment in the technology sector [S2].
What companies has Afinum acquired recently?
Afinum acquired sequrio GmbH in April 2026, p36 GmbH in February 2026, and Ergon Informatik AG in January 2026, per the firm’s news disclosures [S2]. Additional recent acquisitions include DPS Engineering GmbH in December 2025 and ProJect Pharmaceutics in September 2024 [S2][S3].
Where is Afinum based and how big is the firm?
Afinum is headquartered in Munich, Germany, with additional offices in Frankfurt and Zurich [S1]. The firm reports approximately €1.8 billion in total capital commitments across six fund generations as of April 2026 [S1].
Is Afinum still actively acquiring?
Yes, Afinum completed its most recent acquisition of sequrio GmbH in April 2026 and has executed five platform acquisitions in the trailing 18 months, indicating active deployment [S2].
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.